What biosimilar threat? Roche wins another reprieve as FDA stiff-arms Novartis Rituxan copyadmin 3rd May 2018 Uncategorised 0
Cue the relief in Basel: Roche’s Rituxan just got another biosimilar break. Rival drugmaker Novartis says its knockoff version didn’t pass muster at the FDA, and that setback follows another for would-be Rituxan copycat Celltrion. The upshot? No U.S. biosims are likely this year.
More: What biosimilar threat? Roche wins another reprieve as FDA stiff-arms Novartis Rituxan copy